SCYNEXIS, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
SCYNEXIS, Inc. (SCYX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$10.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-10
- SCYNEXIS, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $15.41M.
- SCYNEXIS, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$9.11M, a 736.10% decline year-over-year.
- SCYNEXIS, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $1.43M.
- SCYNEXIS, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$18.90M.
- SCYNEXIS, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $4.85M.
- SCYNEXIS, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$18.00M.
- SCYNEXIS, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$11.44M.
- SCYNEXIS, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$58.67M, a 615.19% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.77M 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $15.41M 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $4.85M 10-K · filed 2026-03-04 | |||
| 2025-09-30 | -$1.61M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | -$5.33M 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | -$9.11M 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | -$18.00M 10-K · filed 2026-03-04 | |||
| 2024-09-30 | -$5.32M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | -$8.06M 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $1.43M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$11.44M 10-K · filed 2025-03-12 | |||
| 2023-09-30 | -$1.42M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $12.47M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$18.90M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$58.67M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | -$35.86M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $14.21M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$9.27M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $11.39M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $7.01M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $19.40M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | -$1.03M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $51.12M 10-K · filed 2022-03-29 | |||
| 2020-09-30 | -$12.43M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | -$7.90M 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | -$21.67M 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $30.43M 10-K · filed 2021-03-29 | |||
| 2019-09-30 | $125.00K 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | $7.71M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $1.51M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $298.00K 10-K · filed 2020-03-11 | |||
| 2018-09-30 | $4.94M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | -$4.37M 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $16.08M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | -$24.19M 10-K · filed 2019-03-14 | |||
| 2017-09-30 | -$26.91M 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | -$28.21M 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | -$15.75M 10-Q · filed 2018-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |